Alternatively, some studies have suggested that the mammalian target of rapamycin (mTOR) inhibitors is a treatment option for Xp11.2 tRCC [21]. Here, MTOR is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.